Amylin/Lilly Eye Byetta sNDA As Monotherapy In 1H 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly tells DAILY that as monotherapy for type 2 diabetes, exenatide could be prescribed to patients earlier in treatment.
You may also be interested in...
Amylin CEO: Firm Can Do Better With Byetta
Diabetes drug so far has failed to catch on with primary-care docs.
Amylin CEO: Firm Can Do Better With Byetta
Diabetes drug so far has failed to catch on with primary-care docs.
Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics
After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.